Voloridge Investment Management
ITOS

Voloridge Investment Management’s iTeos Therapeutics ITOS Stock Holding History

Voloridge Investment Management’s Portfolio ITOS Stock Details ITOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-11,952
Closed -$163K – 1459
2023
Q1 		$163K Sell
11,952
-43,739
-79% -$784K ﹤0.01% 1322
2022
Q4 		$1.09M Sell
55,691
-46,260
-45% -$904K 0.01% 1117
2022
Q3 		$1.94M Buy
101,951
+17,016
+20% +$392K 0.01% 993
2022
Q2 		$1.75M Sell
84,935
-13,750
-14% -$326K 0.01% 1054
2022
Q1 		$3.18M Buy
+98,685
New +$3.59M 0.02% 801

Other funds holding ITOS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Voloridge Investment Management's ITOS Position: Q2 2023 in Review

Voloridge Investment Management sold out of iTeos Therapeutics (ITOS) in Q2 2023, closing a stake of 11,952 shares — an estimated $163K sold.

Voloridge Investment Management first reported a position in ITOS in Q1 2022 and held it in 5 quarters. The position peaked at $3.18M in Q1 2022. 146 funds tracked by Wall St. Rank hold ITOS as of Q2 2023.

  • Voloridge Investment Management reported no remaining iTeos Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Voloridge Investment Management sold 11,952 iTeos Therapeutics shares in Q2 2023, an estimated $163K.
  • Voloridge Investment Management first reported a position in iTeos Therapeutics in Q1 2022 and held it in 5 quarters.
  • Voloridge Investment Management's iTeos Therapeutics position peaked at $3.18M in Q1 2022.
  • 146 funds tracked by Wall St. Rank held iTeos Therapeutics as of Q2 2023.

Based on Voloridge Investment Management's 13F filing for Q2 2023, filed 14 Aug 2023.